Role of trastuzumab in the management of HER2-positive metastatic breast cancer

References

• BroekxSHondEDTorfsRThe costs of breast cancer prior to and following diagnosisEur J Health Econ Epub2010320
   Web of Science ®Google Scholar
• KatanodaKYako-SuketomoHComparison of time trends in breast cancer mortality (1990–2006) in the world, from the WHO mortality database [abstract]Jpn J Clin Oncol20104018220118169
   PubMed Web of Science ®Google Scholar
• SlamonDJClarkGMWongSGLevinWJUllrichAMcGuireWLHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience19872351771823798106
   PubMed Web of Science ®Google Scholar
• SlamonDJGodolphinWJonesLAStudies of the HER-2/neu proto-oncogene in human breast and ovarian cancerScience19892447077122470152
   PubMed Web of Science ®Google Scholar
• HarariDYardenYMolecular mechanisms underlying ErbB2/HER2 action in breast cancerOncogene2000196102611411156523
   PubMed Web of Science ®Google Scholar
• OwensMHortenBDa SilvaMHER2 Amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissuesClin Breast Cancer20045636915140287
   PubMedGoogle Scholar
• BenderLMNahtaRHer2 cross talk and therapeutic resistance in breast cancerFront Biosci2008133906391218508484
   PubMed Web of Science ®Google Scholar
• YardenYSliwkowskiMXUntangling the ErbB signalling networkNat Rev Mol Cell Biol2001212713711252954
   PubMed Web of Science ®Google Scholar
• ValabregaGMontemurroFAgliettaMTrastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancerAnn Oncol20071897798417229773
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med200134478379211248153
   PubMed Web of Science ®Google Scholar
• SauterGLeeJBartlettJMSlamonDJPressMFGuidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerationsJ Clin Oncol2009271323133319204209
   PubMed Web of Science ®Google Scholar
• GancbergDJarvinenTdiLAEvaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testingBreast Cancer Res Treat20027411312012186371
   PubMed Web of Science ®Google Scholar
• PressMFSauterGBernsteinLDiagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trialsClin Cancer Res2005116598660716166438
   PubMed Web of Science ®Google Scholar
• MiddletonLPPriceKMPuigPImplementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive casesArch Pathol Lab Med200913377578019415952
   PubMed Web of Science ®Google Scholar
• CoussensLYang-FengTLLiaoYCTyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogeneScience1985230113211392999974
   PubMed Web of Science ®Google Scholar
• ClynesRATowersTLPrestaLGRavetchJVInhibitory Fc receptors modulate in vivo cytoxicity against tumor targetsNat Med2000644344610742152
   PubMed Web of Science ®Google Scholar
• GennariRMenardSFagnoniFPilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2Clin Cancer Res2004105650565515355889
   PubMed Web of Science ®Google Scholar
• RepkaTChioreanEGGayJTrastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot studyClin Cancer Res200392440244612855616
   PubMed Web of Science ®Google Scholar
• MusolinoANaldiNBortesiBImmunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancerJ Clin Oncol2008261789179618347005
   PubMed Web of Science ®Google Scholar
• TamuraKShimizuCKoizumiFCorrelation of Fc{gamma} R IIa-H131R and IIIa-V158F polymorphisms and clinical outcome of trastuzumab in both neoadjuvant and metastatic setting in patients with HER-2 positive breast cancer [abstract]J Clin Oncol (Meeting Abstracts)2009271100
   Web of Science ®Google Scholar
• BibeauFLopez-CrapezEDiFFImpact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecanJ Clin Oncol2009271122112919164213
   PubMed Web of Science ®Google Scholar
• Lopez-AlbaiteroALeeSCMorganSRole of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cellsCancer Immunol Immunother2009581853186419319529
   PubMed Web of Science ®Google Scholar
• BeanoASignorinoEEvangelistaACorrelation between NK function and response to trastuzumab in metastatic breast cancer patientsJ Transl Med200862518485193
   PubMed Web of Science ®Google Scholar
• VarchettaSGibelliNOlivieroBElements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2Cancer Res200767119911199918089830
   PubMed Web of Science ®Google Scholar
• MozaffariFLindemalmCChoudhuryANK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapyBr J Cancer20079710511117551492
   PubMed Web of Science ®Google Scholar
• LewisGDFigariIFendlyBDifferential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodiesCancer Immunol Immunother1993372552638102322
   PubMed Web of Science ®Google Scholar
• LeXFClaretFXLammayotAThe role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibitionJ Biol Chem2003278234412345012700233
   PubMed Web of Science ®Google Scholar
• HudziakRMLewisGDWingetMFendlyBMShepardHMUllrichAp185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factorMol Cell Biol19899116511722566907
   PubMed Web of Science ®Google Scholar
• BrunoRWashingtonCBLuJFLiebermanGBankenLKleinPPopulation pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancerCancer Chemother Pharmacol20055636136915868146
   PubMed Web of Science ®Google Scholar
• BaselgaJTripathyDMendelsohnJPhase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancerJ Clin Oncol1996147377448622019
   PubMed Web of Science ®Google Scholar
• BaselgaJCarbonellXCastaneda-SotoNJPhase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly scheduleJ Clin Oncol2005232162217115800309
   PubMed Web of Science ®Google Scholar
• GhahramaniPBartonCLeyland-JonesBPharmacokinetics of herceptin administered three-weekly compared to weekly: a simulation based on data from the clinical studies [abstract]The Breast200312S40
   Google Scholar
• VogelCLCobleighMATripathyDEfficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancerJ Clin Oncol20022071972611821453
   PubMed Web of Science ®Google Scholar
• HolligerPHudsonPJEngineered antibody fragments and the rise of single domainsNat Biotechnol2005231126113616151406
   PubMed Web of Science ®Google Scholar
• BakerJHLindquistKEHuxhamLAKyleAHSyJTMinchintonAIDirect visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenograftsClin Cancer Res2008142171217918381959
   PubMed Web of Science ®Google Scholar
• JainRKBaxterLTMechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressureCancer Res198848702270323191477
   PubMed Web of Science ®Google Scholar
• JainRKPhysiological barriers to delivery of monoclonal antibodies and other macromolecules in tumorsCancer Res199050814s819s2404582
   PubMed Web of Science ®Google Scholar
• ParkIHRoJLeeKSNamBHKwonYShinKHTrastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancerAnn Oncol200920566218664558
   PubMed Web of Science ®Google Scholar
• StemmlerHJSchmittMWillemsABernhardHHarbeckNHeinemannVRatio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrierAnticancer Drugs200718232817159499
   PubMed Web of Science ®Google Scholar
• CobleighMAVogelCLTripathyDMultinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic diseaseJ Clin Oncol1999172639264810561337
   PubMed Web of Science ®Google Scholar
• MartyMCognettiFMaraninchiDRandomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study groupJ Clin Oncol2005234265427415911866
   PubMed Web of Science ®Google Scholar
• PegramMDSlamonDJCombination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivitySemin Oncol199926899510482199
   PubMed Web of Science ®Google Scholar
• EstevaFJValeroVBooserDPhase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancerJ Clin Oncol2002201800180811919237
   PubMed Web of Science ®Google Scholar
• JahanzebMMortimerJEYunusFPhase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancerOncologist2002741041712401903
   PubMed Web of Science ®Google Scholar
• BursteinHJHarrisLNMarcomPKTrastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithmJ Clin Oncol2003212889289512885806
   PubMed Web of Science ®Google Scholar
• SledgeGW JrGemcitabine, paclitaxel, and trastuzumab in metastatic breast cancerOncology (Williston Park)200317333514768403
   PubMedGoogle Scholar
• BianchiGAlbanellJEiermannWPilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancerClin Cancer Res200395944595114676119
   PubMed Web of Science ®Google Scholar
• PegramMDPienkowskiTNorthfeltDWResults of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancerJ Natl Cancer Inst20049675976915150304
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJAVukeljaSMarslandTKimmelGRatnamSPippenJEPhase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancerClin Breast Cancer2004514214715245619
   PubMedGoogle Scholar
• ChiaSClemonsMMartinLAPegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trialJ Clin Oncol2006242773277816682726
   PubMed Web of Science ®Google Scholar
• RobertNLeyland-JonesBAsmarLRandomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancerJ Clin Oncol2006242786279216782917
   PubMed Web of Science ®Google Scholar
• SchallerGFuchsIGonschTPhase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanesJ Clin Oncol2007253246325017577021
   PubMed Web of Science ®Google Scholar
• AndreopoulouEGaiottiDKimEFeasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancerClin Breast Cancer2007769069617919349
   PubMed Web of Science ®Google Scholar
• CortesJDiCSClimentMANonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II studyClin Cancer Res20091530731419118059
   PubMed Web of Science ®Google Scholar
• ChristodoulouCKostopoulosIKalofonosHPTrastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. Phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluationOncology20097627528519262067
   PubMed Web of Science ®Google Scholar
• StickelerEKlarMWatermannDPegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trialBreast Cancer Res Treat200911759159819156515
   PubMed Web of Science ®Google Scholar
• VenturiniMBighinCPuglisiFA multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancerBreast201019533333820185313
   PubMed Web of Science ®Google Scholar
• MontemurroFChoaGFaggiuoloRSafety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II studyAm J Clin Oncol200326959712576933
   PubMed Web of Science ®Google Scholar
• MontemurroFRedanaSVialeGRetrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib eraClin Breast Cancer2008843644218952558
   PubMed Web of Science ®Google Scholar
• GelmonKAMackeyJVermaSUse of trastuzumab beyond disease progression: observations from a retrospective review of case historiesClin Breast Cancer20045525815140285
   PubMedGoogle Scholar
• vonMGduBASchmidtMTrastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03–05 studyJ Clin Oncol2009271999200619289619
   PubMed Web of Science ®Google Scholar
• GeyerCEForsterJLindquistDLapatinib plus capecitabine for HER2-positive advanced breast cancerN Engl J Med20063552733274317192538
   PubMed Web of Science ®Google Scholar
• LinNUDierasVPaulDMulticenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancerClin Cancer Res2009151452145919228746
   PubMed Web of Science ®Google Scholar
• BlackwellKLBursteinHJStornioloAMRandomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancerJ Clin Oncol2010281124113020124187
   PubMed Web of Science ®Google Scholar
• DowsettMAllredCKnoxJRelationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trialJ Clin Oncol2008261059106518227529
   PubMed Web of Science ®Google Scholar
• RasmussenBBReganMMLykkesfeldtAEAdjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1–98 randomised trialLancet Oncol20089232818083065
   PubMed Web of Science ®Google Scholar
• DowsettMHarper-WynneCBoeddinghausIHER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancerCancer Res2001618452845811731427
   PubMed Web of Science ®Google Scholar
• ArpinoGWeissHLeeAVEstrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistanceJ Natl Cancer Inst2005971254126116145046
   PubMed Web of Science ®Google Scholar
• KaufmanBMackeyJRClemensMRTrastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM studyJ Clin Oncol2009275529553719786670
   PubMed Web of Science ®Google Scholar
• JohnstonSPippenJ JrPivotXLapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancerJ Clin Oncol2009275538554619786658
   PubMed Web of Science ®Google Scholar
• SchwartzbergLSFrancoSXFloranceAO’RourkeLMaltzmanJJohnstonSLapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancerOncologist20101512212920156908
   PubMed Web of Science ®Google Scholar
• SpectorNLBlackwellKLUnderstanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancerJ Clin Oncol2009275838584719884552
   PubMed Web of Science ®Google Scholar
• StemmlerHJKahlertSSiekieraWUntchMHeinrichBHeinemannVProlonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC)Onkologie20052858258616249644
   PubMed Web of Science ®Google Scholar
• NahtaREstevaFJTrastuzumab: triumphs and tribulationsOncogene2007263637364317530017
   PubMed Web of Science ®Google Scholar
• CitriAYardenYEGF-ERBB signalling: towards the systems levelNat Rev Mol Cell Biol2006750551616829981
   PubMed Web of Science ®Google Scholar
• SerginaNVRauschMWangDEscape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3Nature200744543744117206155
   PubMed Web of Science ®Google Scholar
• NagataYLanKHZhouXPTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell2004611712715324695
   PubMed Web of Science ®Google Scholar
• BernsKHorlingsHMHennessyBTA functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancerCancer Cell20071239540217936563
   PubMed Web of Science ®Google Scholar
• BelkhiriADarAAPengDFExpression of t-DARPP mediates trastuzumab resistance in breast cancer cellsClin Cancer Res2008144564457118579663
   PubMed Web of Science ®Google Scholar
• HamelSBouchardAFerrarioCBoth t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancersBreast Cancer Res Treat2010120475719301121
   PubMed Web of Science ®Google Scholar
• ChenFLXiaWSpectorNLAcquired resistance to small molecule ErbB2 tyrosine kinase inhibitorsClin Cancer Res2008146730673418980964
   PubMed Web of Science ®Google Scholar
• XiaWBacusSHegdePA model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancerProc Natl Acad Sci U S A20061037795780016682622
   PubMed Web of Science ®Google Scholar
• XiaWBisiJStrumJRegulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancersCancer Res2006661640164716452223
   PubMed Web of Science ®Google Scholar
• AsanumaHTorigoeTKamiguchiKSurvivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cellsCancer Res200565110181102516322251
   PubMed Web of Science ®Google Scholar
• OzbayTDurdenDLLiuTO’ReganRMNahtaRIn vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cellsCancer Chemother Pharmacol20106569770619636556
   PubMed Web of Science ®Google Scholar
• NahtaRYuDHungMCHortobagyiGNEstevaFJMechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancerNat Clin Pract Oncol2006326928016683005
   PubMedGoogle Scholar
• MotoyamaABHynesNELaneHAThe efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptidesCancer Res2002623151315812036928
   PubMed Web of Science ®Google Scholar
• DiermeierSHorvathGKnuechel-ClarkeRHofstaedterFSzollosiJBrockhoffGEpidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activationExp Cell Res200530460461915748904
   PubMed Web of Science ®Google Scholar
• ValabregaGMontemurroFSarottoITGFalpha expression impairs Trastuzumab-induced HER2 downregulationOncogene2005243002301015735715
   PubMed Web of Science ®Google Scholar
• RitterCAPerez-TorresMRinehartCHuman breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor networkClin Cancer Res2007134909491917699871
   PubMed Web of Science ®Google Scholar
• LuYZiXZhaoYMascarenhasDPollakMInsulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)J Natl Cancer Inst2001931852185711752009
   PubMed Web of Science ®Google Scholar
• NahtaRYuanLXZhangBKobayashiREstevaFJInsulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cellsCancer Res200565111181112816322262
   PubMed Web of Science ®Google Scholar
• LindemannKResauJNahrigJDifferential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissueHistopathology200751546217593080
   PubMed Web of Science ®Google Scholar
• ShattuckDLMillerJKCarrawayKL IIISweeneyCMet receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cellsCancer Res2008681471147718316611
   PubMed Web of Science ®Google Scholar
• NakshatriHBhat-NakshatriPMartinDAGouletRJ JrSledgeGW JrConstitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growthMol Cell Biol199717362936399199297
   PubMed Web of Science ®Google Scholar
• NakshatriHGouletRJ JrNF-kappaB and breast cancerCurr Probl Cancer20022628230912429950
   PubMed Web of Science ®Google Scholar
• CardosoFDurbecqVLaesJFBortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic mannerMol Cancer Ther200653042305117148762
   PubMed Web of Science ®Google Scholar
• MolinaMACodony-ServatJAlbanellJRojoFArribasJBaselgaJTrastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cellsCancer Res2001614744474911406546
   PubMed Web of Science ®Google Scholar
• NagyPFriedlanderETannerMDecreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell lineCancer Res20056547348215695389
   PubMed Web of Science ®Google Scholar
• FesslerSPWotkowiczMTMahantaSKBamdadCMUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cellsBreast Cancer Res Treat200911811312419415485
   PubMed Web of Science ®Google Scholar
• Palyi-KrekkZBarokMIsolaJTammiMSzollosiJNagyPHyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancerEur J Cancer2007432423243317911008
   PubMed Web of Science ®Google Scholar
• BussolatiGMontemurroFRighiLDonadioMAgliettaMSapinoAA modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancerBr J Cancer2005921261126715812476
   PubMed Web of Science ®Google Scholar
• SapinoAMontemurroFMarchioCPatients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating studyAnn Oncol2007181963196817785760
   PubMed Web of Science ®Google Scholar
• HudelistGKostlerWJAttemsJHer-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatmentBr J Cancer20038998399112966413
   PubMed Web of Science ®Google Scholar
• LiuPCLiuXLiYIdentification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cellsCancer Biol Ther2006565766416627989
   PubMed Web of Science ®Google Scholar
• LiuXFridmanJSWangQSelective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumabCancer Biol Ther2006564865616627988
   PubMed Web of Science ®Google Scholar
• KostlerWJSchwabBSingerCFMonitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancerClin Cancer Res2004101618162415014012
   PubMed Web of Science ®Google Scholar
• ColomerRLlombart-CussacALluchABiweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domainAnn Oncol20041520120614760109
   PubMed Web of Science ®Google Scholar
• FornierMNSeidmanADSchwartzMKSerum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rateAnn Oncol20051623423915668276
   PubMed Web of Science ®Google Scholar
• LennonSBartonCBankenLUtility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancerJ Clin Oncol2009271685169319255335
   PubMed Web of Science ®Google Scholar
• SeidmanAHudisCPierriMKCardiac dysfunction in the trastuzumab clinical trials experienceJ Clin Oncol2002201215122111870163
   PubMed Web of Science ®Google Scholar
• UntchMMuschollMTjulandinSFirst-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trialJ Clin Oncol2010281473148020177030
   PubMed Web of Science ®Google Scholar
• SeidmanADFornierMNEstevaFJWeekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplificationJ Clin Oncol2001192587259511352950
   PubMed Web of Science ®Google Scholar
• GuarneriVLenihanDJValeroVLong-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experienceJ Clin Oncol2006244107411516908934
   PubMed Web of Science ®Google Scholar
• RomondEHPerezEABryantJTrastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerN Engl J Med20053531673168416236738
   PubMed Web of Science ®Google Scholar
• Piccart-GebhartMJProcterMLeyland-JonesBTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancerN Engl J Med20053531659167216236737
   PubMed Web of Science ®Google Scholar
• SlamonDIermannWRobertNPhase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC≥T) with Doxorubicin and Cyclophosphamide followed by Docetaxel and Trastuzumab (AC≥TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in HER2neu Positive Early Breast Cancer Ppatients: BCIRG006 Study [abstract]Cancer Res200969
   Web of Science ®Google Scholar
• JoensuuHBonoPKatajaVFluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer TrialJ Clin Oncol2009275685569219884557
   PubMed Web of Science ®Google Scholar
• Tan-ChiuEYothersGRomondEAssessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31J Clin Oncol2005237811781916258083
   PubMed Web of Science ®Google Scholar
• PerezEASumanVJDavidsonNECardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trialJ Clin Oncol2008261231123818250349
   PubMed Web of Science ®Google Scholar
• ProcterMSuterTMdeAELonger-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trialJ Clin Oncol2010283422342820530280
   PubMed Web of Science ®Google Scholar
• McArthurHLChiaSCardiotoxicity of trastuzumab in clinical practiceN Engl J Med2007357949517611218
   PubMed Web of Science ®Google Scholar
• MontemurroFRedanaSValabregaGMartinelloRAgliettaMPalmieroRTrastuzumab-related cardiotoxicity in the herceptin adjuvant trialJ Clin Oncol2008262052205318421060
   PubMed Web of Science ®Google Scholar
• SuterTMProcterMvan VeldhuisenDJTrastuzumab-associated cardiac adverse effects in the herceptin adjuvant trialJ Clin Oncol2007253859386517646669
   PubMed Web of Science ®Google Scholar
• TelliMLHuntSACarlsonRWGuardinoAETrastuzumab-related cardiotoxicity: calling into question the concept of reversibilityJ Clin Oncol2007253525353317687157
   PubMed Web of Science ®Google Scholar
• CardinaleDColomboATorrisiRTrastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluationJ Clin Oncol2010283910391620679614
   PubMed Web of Science ®Google Scholar
• EwerMSVooletichMTDurandJBReversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatmentJ Clin Oncol2005237820782616258084
   PubMed Web of Science ®Google Scholar
• MunozJSheqwaraJArangoBAliHYLoutfiRWeaverDWThe role of beta-blockers and ACE inhibitors in the prevention of trastuzumab-related cardiotoxicity [abstract]J Clin Oncol (Meeting Abstracts)201028555
   Web of Science ®Google Scholar
• BuzdarAUIbrahimNKFrancisDSignificantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancerJ Clin Oncol2005233676368515738535
   PubMed Web of Science ®Google Scholar
• GianniLEiermannWSemiglazovVNeoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortLancet201037537738420113825
   PubMed Web of Science ®Google Scholar
• TanchiuEKaufmanPAPaikSregistHER: a prospective, longitudinal cohort study of women with HER2 positive metastatic breast cancer [abstract]J Clin Oncol (Meeting Abstracts)200523670
   Web of Science ®Google Scholar
• TripathyDKaufmanPBrufskyAregistHER: treatment outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR+) metastatic breast cancer (MBC) [abstract]J Clin Oncol (Meeting Abstracts)2009271057
   Web of Science ®Google Scholar
• TripathyDSlamonDJCobleighMSafety of treatment of metastatic breast cancer with trastuzumab beyond disease progressionJ Clin Oncol2004221063107015020607
   PubMed Web of Science ®Google Scholar
• FountzilasGRazisETsavdaridisDContinuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology groupClin Breast Cancer2003412012512864940
   PubMedGoogle Scholar
• RabindranSKDiscafaniCMRosfjordECAntitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinaseCancer Res2004643958396515173008
   PubMed Web of Science ®Google Scholar
• BursteinHJSunYDirixLYNeratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancerJ Clin Oncol2010281301130720142587
   PubMed Web of Science ®Google Scholar
• AwadaADirixLBeckJSafety and efficacy of Neratinib (HKI-272) in combination with Vinorelbine in ErbB2+ metastatic breast cancer [abstract]Cancer Res2009695095
   Web of Science ®Google Scholar
• ChowLGuptaSHershmanDSafety and efficacy of Neratinib (HKI-272) in combination with Paclitaxel in ErbB2+ metastatic breast cancer [abstract]Cancer Res2009695081
   Web of Science ®Google Scholar
• SauraCMartinMMorooseRSafety of Neratinib (HKI-272) in combination with Capecitabine in patients with solid tumors: a Phase 1/2 study [abstract]Cancer Res200969510819509222
   PubMed Web of Science ®Google Scholar
• AdamsCWAllisonDEFlagellaKHumanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumabCancer Immunol Immunother20065571772716151804
   PubMed Web of Science ®Google Scholar
• FranklinMCCareyKDVajdosFFLeahyDJde VosAMSliwkowskiMXInsights into ErbB signaling from the structure of the ErbB2-pertuzumab complexCancer Cell2004531732815093539
   PubMed Web of Science ®Google Scholar
• CortesJBaselgaJPetrellaTPertuzumab monotherapy following trastuzumab-based treatment: activity and tolerability in patients with advanced HER2-positive breast cancer [abstract]J Clin Oncol (Meeting Abstracts)2009271022
   Web of Science ®Google Scholar
• BaselgaJGelmonKAVermaSPhase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapyJ Clin Oncol2010281138114420124182
   PubMed Web of Science ®Google Scholar
• Lewis PhillipsGDLiGDuggerDLTargeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugateCancer Res2008689280929019010901
   PubMed Web of Science ®Google Scholar
• KropIEBeeramMModiSPhase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancerJ Clin Oncol2010282698270420421541
   PubMed Web of Science ®Google Scholar
• MillerKGianniLAndreFA phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T) [abstract]J Clin Oncol (Meeting Abstracts)2010281012
   Web of Science ®Google Scholar
• PerezEDirixLKocsisJEfficacy and safety of Trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: preliminary results of a randomized multicenter, open label phase 2 study (TDM4450G) [abstract]Ann Oncol (meeting Abstracts)201021viii2
   Web of Science ®Google Scholar